Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariz

Showing results (691-700 of 732) with videos related to

Pageof 74
Sort By:
Skeletal Muscle|December 15, 2015
CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophyFernanda Pinto-Mariz, Luciana Rodrigues Carvalho, Alexandra Prufer De Queiroz Campos Araujo, et al.
Advances in Rheumatology (London, England)|November 26, 2025
VII Brazilian Consensus guidelines for the detection and interpretation of anti-cell autoantibodies on HEp-2 cellsWilson de Melo Cruvinel, Paulo Luiz Carvalho Francescantônio, Wilton Ferreira Silva Santos, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2021
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III StudyLarry W Kwak, Juan-Manuel Sancho, Seok-Goo Cho, et al.
Cancers|May 28, 2020
PLZF-RAR<sub>α</sub>, NPM1-RAR<sub>α</sub>, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature ReviewMarta Sobas, Maria Carme Talarn-Forcadell, David Martínez-Cuadrón, et al.
Chemico-Biological Interactions|January 26, 2018
New 1,3-benzodioxole derivatives: Synthesis, evaluation of in vitro schistosomicidal activity and ultrastructural analysisLuana Maria Mariz Gomes da Silva, Jamerson Ferreira de Oliveira, Willams Leal Silva, et al.
The Lancet. Haematology|November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trialMichinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Viruses|March 30, 2023
Human Genome Polymorphisms and Computational Intelligence Approach Revealed a Complex Genomic Signature for COVID-19 Severity in Brazilian PatientsAndré Filipe Pastor, Cássia Docena, Antônio Mauro Rezende, et al.
Brain : a Journal of Neurology|February 5, 2013
K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivityNancy Mokbel, Biljana Ilkovski, Michaela Kreissl, et al.
Oral Diseases|November 18, 2025
Machine Learning Classification of Palatal Salivary Gland Tumors Using Clinical and Demographic DescriptorsLuís Arthur de Melo Tassinari, Anna Luíza Damaceno Araújo, Sebastião Silvério de Sousa-Neto, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Pageof 74

Showing results (691-700 of 732) with videos related to

Sort By:
Pageof 74
Skeletal Muscle|December 15, 2015
CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophyFernanda Pinto-Mariz, Luciana Rodrigues Carvalho, Alexandra Prufer De Queiroz Campos Araujo, et al.
Advances in Rheumatology (London, England)|November 26, 2025
VII Brazilian Consensus guidelines for the detection and interpretation of anti-cell autoantibodies on HEp-2 cellsWilson de Melo Cruvinel, Paulo Luiz Carvalho Francescantônio, Wilton Ferreira Silva Santos, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 23, 2021
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III StudyLarry W Kwak, Juan-Manuel Sancho, Seok-Goo Cho, et al.
Cancers|May 28, 2020
PLZF-RAR<sub>α</sub>, NPM1-RAR<sub>α</sub>, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature ReviewMarta Sobas, Maria Carme Talarn-Forcadell, David Martínez-Cuadrón, et al.
Chemico-Biological Interactions|January 26, 2018
New 1,3-benzodioxole derivatives: Synthesis, evaluation of in vitro schistosomicidal activity and ultrastructural analysisLuana Maria Mariz Gomes da Silva, Jamerson Ferreira de Oliveira, Willams Leal Silva, et al.
The Lancet. Haematology|November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trialMichinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Viruses|March 30, 2023
Human Genome Polymorphisms and Computational Intelligence Approach Revealed a Complex Genomic Signature for COVID-19 Severity in Brazilian PatientsAndré Filipe Pastor, Cássia Docena, Antônio Mauro Rezende, et al.
Brain : a Journal of Neurology|February 5, 2013
K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivityNancy Mokbel, Biljana Ilkovski, Michaela Kreissl, et al.
Oral Diseases|November 18, 2025
Machine Learning Classification of Palatal Salivary Gland Tumors Using Clinical and Demographic DescriptorsLuís Arthur de Melo Tassinari, Anna Luíza Damaceno Araújo, Sebastião Silvério de Sousa-Neto, et al.
The Lancet. Oncology|December 10, 2020
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 studyJacob P Laubach, Fredrik Schjesvold, Mário Mariz, et al.
Pageof 74